Matt Kazan provides strategic advice to health plan and life sciences clients navigating the complex legislative and regulatory policy environment, with a particular expertise in Medicare Part D and Medicare Advantage.

Prior to joining Avalere, Matt spent over a decade on the US Senate Committee on Finance health staff under Senators Max Baucus and Ron Wyden. As senior health policy adviser, Matt was the primary policy adviser on policy issues, including Medicare Advantage, Medicare Part D and all drug reimbursement under Medicare, chronic disease, dual eligibles, post-acute care, the Medicare Shared Savings Program, and Medicare and Medicaid program integrity. During his tenure, Matt was involved in a variety of major legislative efforts including the Affordable Care Act, the Bipartisan Budget Act of 2018, the Medicare Access and CHIP Reauthorization Act of 2015, the Children’s Health Insurance Program Reauthorization Act of 2009, and the American Recovery and Reinvestment Act.

Matt holds an undergraduate degree from the University of Denver and a Master of Public Policy from the George Washington University.

Authored Content


As the Centers for Medicare & Medicaid Services (CMS) consider what, if any, changes to propose to Medicare Advantage (MA) through fall rulemaking, stakeholders should consider where the Biden administration’s priorities may differ from the previous administration’s. Topics that may be addressed—either in regulation or via legislation—include health equity, supplemental benefit flexibility, star ratings, payment and risk adjustment, and end-stage renal disease (ESRD).

In his first address to Congress, President Biden signaled that healthcare will continue to be a high priority for his administration, specifically highlighting pandemic response, drug pricing priorities (e.g., Medicare negotiation), and Affordable Care Act (ACA) enhancements.

Join Avalere’s panel of data analytics, market access, and policy experts for a discussion on the potential for federal drug pricing reform in Congress or via administrative action.

A second reconciliation package could include significant drug pricing reforms as a means to pay for permanent coverage expansion and other top priorities.

Tune into another episode in the Avalere Health Essential Voice podcast series focused on COVID-19. In this segment, Richard Ashworth, President and CEO of Tivity Health, joins us to discuss survey findings around COVID-19 and the senior population, with key takeaways related to vaccination acceptance and hesitancy.

The COVID-19 public health emergency, new policy changes, and existing unmet patient needs will pressure the evolving payer, provider, and reimbursement landscape for kidney care in 2021.

New Avalere analysis finds that 3 proposals to redesign the Part D benefit—H.R.19/S.3129, Prescription Drug Price Reduction Act (PDPRA), and Elijah Cummings Lower Drug Costs Now Act (H.R.3)—would increase 2023 mandatory manufacturer discounts by 80%, 81%, and 283%, respectively, with significant variation across therapeutic areas.

Recent regulatory action released in the final days of the Trump administration related to Medicare Advantage (MA) and Part D could significantly impact plan and manufacturer calendar year (CY) 2022 contracting strategies and stakeholder advocacy priorities.

The outcome of Georgia’s runoff election—resulting in a Democratic majority in the Senate—combined with the existing Democratic majority in the House and incoming Biden administration, significantly changes the policy outlook for 2021.

The accelerated changes and increased uncertainties in healthcare brought on by the COVID-19 pandemic will continue into 2021, and its impacts are likely to shape healthcare for years to come. While prevalent uncertainty is a given, the broad outline of a new era is already emerging. More than ever, careful examination of healthcare stakeholder’s business models, policy developments, and data will be essential to arrive at accurate assessments of the future state. Our experts engaged in a live discussion covering critical issues facing healthcare leaders and strategies for clearing the path.

Earlier today, the Trump Administration released long-anticipated drug pricing reforms, including rules related to a Most Favored Nation (MFN) approach for drugs administered by providers in Medicare and rebate reform for the Medicare Part D program. Both rules represent fundamental shifts in our current system and have significant implications for manufacturers, health plans, pharmacies, providers, and patients.

The accelerated changes and increased uncertainties in healthcare brought on by the COVID-19 pandemic will continue into 2021, and its impacts are likely to shape healthcare for years to come. While prevalent uncertainty is a given, the broad outline of a new era is already emerging. More than ever, careful examination of healthcare stakeholder’s business models, policy developments, and data will be essential to arrive at accurate assessments of the future state. Our experts engaged in a live discussion covering critical issues facing healthcare leaders and strategies for clearing the path.

For even deeper coverage, download the 2021 Healthcare Industry Outlook document below.

Tune into our seventh video of the Avalere Health Essential Voice: Election 2020 series. As election day approaches, our experts share their thoughts on how the COVID surge has changed the campaigns’ closing arguments, the current outlook on a COVID relief package, and how the election results will affect individual stakeholders.

Tune into our seventh episode of the Avalere Health Essential Voice: Election 2020 series. As election day approaches, our experts share their thoughts on how the COVID surge has changed the campaigns’ closing arguments, the current outlook on a COVID relief package, and how the election results will affect individual stakeholders.

Avalere experts discussed how the 2020 election is influencing the future of healthcare.

Tune into our fifth episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss the evolving makeup of the Supreme Court and the outlook on California vs. Texas — the upcoming Supreme Court case regarding the constitutionality of the Affordable Care Act and, in particular, the individual mandate. 

Tune into the fifth video of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss the evolving makeup of the Supreme Court and the outlook on California vs. Texas — the upcoming Supreme Court case regarding the constitutionality of the Affordable Care Act and, in particular, the individual mandate. 

With the US Supreme Court set to hear arguments starting November 10 on California v. Texas, and Judge Amy Coney Barrett’s nomination under consideration in the Senate, questions remain regarding the future of the law.

Watch the fourth video in the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss top healthcare issues and platforms from the first Presidential debate, including the Affordable Care Act (ACA), COVID-19, public health, health disparities, and drug-pricing reform.

Tune into our fourth episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss top healthcare issues and platforms from the first Presidential debate, including the Affordable Care Act (ACA), COVID-19, public health, health disparities, and drug-pricing reform.

Avalere analysis finds End Stage Renal Disease (ESRD) spending in Puerto Rico varies substantially, and most spending is related to outpatient dialysis and inpatient services.

Tune into our third episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss candidates’ respective approaches to drug pricing policies, and where there is unexpected overlap.

Tune into our third episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss candidates’ respective approaches to drug pricing policies and where there is unexpected overlap.

Yesterday, the Administration released the awaited “Most Favored Nation” Executive Order (EO), which calls for a model that would cap the price Medicare pays for select Part B and D drugs.

Tune into our second episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, experts from the policy and vaccines teams discuss the healthcare themes heard at the recent political conventions, and differences we can expect to see in the candidates’ healthcare platforms.

Tune into our second episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, experts from the policy and vaccines teams discuss the healthcare themes heard at the recent political conventions, and differences we can expect to see in the candidates’ healthcare platforms.

Under the Medicare Advantage (MA) Star Ratings Program, plans with 4-stars or more receive the greatest benefit from the Quality Bonus Program (QBP) in the form of higher benchmarks and bonus payments.

Surprise and balance billing reform efforts have been a subject of ongoing debate at the federal level.

Tune into our first episode of the Avalere Health Essential Voice: 2020 Election series. In this segment, our experts discuss the healthcare disparity issues at the forefront of the 2020 election and which healthcare topics to watch for at the Democratic National Convention.

In the first episode of the 2020 Election with Avalere series, Avalere experts discuss the healthcare disparity issues at the forefront of the 2020 election and which healthcare topics to watch at the Democratic National Convention.

Avalere’s 2020 Election series started with our experts covering the current state of play in the 2020 election and the role of healthcare between now and November.

Dually eligible beneficiaries in Pennsylvania with end-stage renal disease (ESRD) are more often people of color and have higher costs compared to non-duals, but their utilization patterns are similar.

With the release of the 2021 Medicare Advantage (MA) and Part D Final Rule, the details of the upcoming policy change that allows beneficiaries with end-stage renal disease (ESRD) to enroll in MA are set. Stakeholders need to adapt quickly to be prepared.

Faced with a rapidly evolving healthcare environment, there are a number of important uncertainties that commercial insurers will need to consider when planning for the future

On April 9, Avalere experts came together to discuss the impact of COVID-19 on the health insurance industry.

Tune into the eighth episode of our series of podcasts that focuses on COVID-19. In episode 8, Avalere experts from the Policy practice discuss the impact of COVID-19 pandemic on retail pharmacy and pharmacists.

The kidney care payment and delivery landscape was poised for change in 2020 due to existing policies and market trends. Given the specific risk COVID-19 poses to these patients, the pandemic is creating new challenges and potentially accelerating existing trends in the kidney care space.

As COVID-19 continues to stress the US healthcare system, pharmacists and retail pharmacies may help respond to the pandemic.

The COVID-19 pandemic will have ongoing, market-wide implications as Medicare Advantage (MA) plans contend both with responding to the virus and the disruption to their normal activities.

Our panel of experts engaged in an in-depth discussion of the rapidly evolving regulatory environment surrounding COVID-19 testing and treatment and the strategic, financial, and operational challenges this disease presents for health insurers.

Tune into the fifth episode of our series that focuses on COVID-19. In episode 5, Avalere experts from the Policy practice discuss how COVID-19 has impacted the healthcare landscape and policy debate.

The growing prevalence and disparities in chronic diseases necessitate that health plans address food insecurity to improve patient outcomes. The combination of increasing need for access to healthy food and changes in the health policy and insurance landscape create opportunities to address food insecurity through a variety of payers.

Avalere analysis finds that average beneficiary out-of-pocket (OOP) spending for 3 commonly used insulin products remains similar throughout the year, ranging from $95 in December to $136 in June and July.

Avalere analysis finds differences in the demographics of patients with End Stage Renal Disease (ESRD) enrolled in Medicare Advantage (MA) compared to ESRD patients in Fee-for-Service (FFS) Medicare

Avalere analysis finds that many CA beneficiaries enrolled in D-SNP look-alike plans may not be able to a transition to a D-SNP.

This month, the Centers for Medicare & Medicaid Services (CMS) proposed changes to Medicare Advantage (MA) through the annual Advance Rate Notice and Proposed Rule. These proposals impact MA in many ways, including changes to quality bonus payments, network adequacy requirements, coverage of End Stage Renal Disease (ESRD), plans targeting dual eligibles, and supplemental benefit offerings. Stakeholders should examine each of these areas closely as they respond to CMS.

CMS is set to release its annual proposed changes to Medicare Advantage (MA) this week. Some of the topics that may be addressed include End-Stage Renal Disease (ESRD), network adequacy requirements, payment to MA plans that offer the hospice benefit, and the MA quality bonus program.

Avalere analysis finds that payment to Medicare Advantage (MA) plans for end-stage renal disease (ESRD) patients in highly populated regions may be significantly below actual patient costs.

A shifting policy landscape and emerging market forces could introduce significant disruption in the kidney care space in the coming years. Understanding the risks and opportunities that these changes may present will be critical for patients, providers, payers, and manufacturers alike.